Rep. Rosa DeLauro (D-Conn.) made a statement on Monday criticizing the way the Food and Drug Administration (FDA) has handled its decision-making over the diabetes drug Avandia in light of two recent studies. These studies, published in the Journal of the American Medical Association, demonstrated that Avandia led to an increased risk of stroke, heart failure, and death in patients over the age of 65.
These studies support a growing body of evidence from previous analyses of Avandia which claim the drug poses a significant danger to consumers, especially when compared with similar alternatives. As a result, DeLauro has urged the FDA to remove Avandia from the market.
Next month, a federal hearing will be held to determine whether Avandia can remain on the market. The information provided in these two studies does not bode well for Avandia’s long-term survival. In one of the studies released on Monday, Avandia was determined to increase the risk of heart attacks by 28-39% compared with comparable alternative diabetes drugs. The other study found Avandia to increase the risk of stroke by 27%, heart failure by 25%, and death by 13% compared with alternative treatment methods.
If you or a loved one has suffered an injury from taking the diabetes drug Avandia, you may be entitled to receive compensation through a defective drug lawsuit. An experienced pharmaceutical injury lawyer can help you with the filing of your claim.
If you have an Avandia claim in the New York or New Jersey area, please contact the experienced defective drug attorneys at Trief & Olk today to schedule your free initial consultation.
